Clinical Quiz: AGA Guideline for Fecal Microbiota-Based Therapies in Gastrointestinal Disease

Quiz
Article

Test your knowledge of the AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases with this clinical quiz!

On February 21, 2024, the American Gastroenterological Association (AGA) released the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal diseases. A guideline panel developed 7 recommendations intended to provide the basis for rational, informed decision-making for patients and healthcare professionals using fecal microbiota-based therapies for adults with recurrent Clostridioides difficile infection (CDI), severe to fulminant CDI, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).

In this clinical quiz, test your knowledge of the clinical recommendations for the use of fecal microbiota-based therapies in the 2024 American Gastroenterological Association Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.

What does the AGA suggest regarding fecal microbiota-based therapies in severely immunocompromised adults with recurrent CDI?



Reference:

  1. Peery AF, Kelly CR, Kao D, et al. American Gastroenterological Association Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. https://www.gastrojournal.org/article/S0016-5085(24)00041-6/fulltext
Related Videos
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Paul Appelbaum, MD: What to Warn Patients When Prescribing Psychedelics in the Future
Ryan McLaughlin, PhD: Challenges Studying Cannabis to Treat Psychiatric Illness
Andrew Chen, MD: Taking More Adverse Event Prone Anxiety Medications
Andrew Chen, MD: Breaking Down First-Line Treatments, or Alternatives, for Anxiety
© 2024 MJH Life Sciences

All rights reserved.